Farther Finance Advisors LLC Sells 504 Shares of Sanofi $SNY

Farther Finance Advisors LLC reduced its holdings in Sanofi (NASDAQ:SNY) by 8.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,711 shares of the company’s stock after selling 504 shares during the period. Farther Finance Advisors LLC’s holdings in Sanofi were worth $276,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in SNY. Nuveen LLC acquired a new position in Sanofi in the 1st quarter valued at approximately $177,831,000. Federated Hermes Inc. raised its holdings in Sanofi by 58.5% in the 1st quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock valued at $218,933,000 after acquiring an additional 1,456,269 shares in the last quarter. OLD Mission Capital LLC acquired a new position in Sanofi in the 1st quarter valued at approximately $48,938,000. Raymond James Financial Inc. raised its holdings in Sanofi by 15.1% in the 1st quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company’s stock valued at $179,914,000 after acquiring an additional 425,597 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in Sanofi by 8,703.0% in the 1st quarter. GAMMA Investing LLC now owns 335,921 shares of the company’s stock valued at $18,630,000 after acquiring an additional 332,105 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Stock Up 3.4%

NASDAQ:SNY opened at $47.20 on Wednesday. The stock’s fifty day moving average price is $48.19 and its two-hundred day moving average price is $50.21. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The company has a market cap of $115.90 billion, a price-to-earnings ratio of 11.35, a P/E/G ratio of 1.08 and a beta of 0.51.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The firm had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. During the same period in the prior year, the company posted $1.73 EPS. The firm’s quarterly revenue was down 7.0% compared to the same quarter last year. On average, analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $56.00 to $58.00 in a report on Monday, September 8th. Guggenheim reiterated a “buy” rating on shares of Sanofi in a research note on Tuesday, June 3rd. Barclays reiterated an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.